{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:27:00Z","timestamp":1787729220511,"version":"build-2784847793"},"reference-count":158,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"unspecified","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008741","name":"EULAR","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008741","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2022,5,18]]},"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:p>The objectives of this review were to collect and summarise evidence on therapeutic drug monitoring (TDM) of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases and to inform the EULAR Task Force for the formulation of evidence-based points to consider. A systematic literature review (SLR) was performed, covering technical aspects and (clinical) utility of TDM, to answer 13 research questions. MEDLINE, Embase and Cochrane were searched until July 2020. American College of Rheumatology and EULAR abstracts were also considered for inclusion. Data were extracted in evidence tables and risk of bias assessment was performed. For the search on technical aspects, 678 records were identified, of which 22 papers were selected. For the clinical utility search, 3846 records were identified, of which 108 papers were included. Patient-related factors associated with biopharmaceutical blood concentrations included body weight, methotrexate comedication and disease activity. The identification of a target range was hampered by study variability, mainly disease activity measures and study type. Evidence was inconsistent for multiple clinical situations in which TDM is currently applied. However, for some particular scenarios, including prediction of future treatment response, non-response to treatment, tapering and hypersensitivity reactions, robust evidence was found. There is currently no evidence for routine use of proactive TDM, in part because published cost-effectiveness analyses do not incorporate the current landscape of biopharmaceutical costs and usage. This SLR yields evidence in favour of TDM of biopharmaceuticals in some clinical scenarios, but evidence is insufficient to support implementation of routine use of TDM.<\/jats:p>","DOI":"10.1136\/rmdopen-2022-002216","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T11:30:56Z","timestamp":1654255856000},"page":"e002216","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":23,"title":["Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6591-7838","authenticated-orcid":false,"given":"Charlotte","family":"Krieckaert","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2630-3312","authenticated-orcid":false,"given":"Borja","family":"Hern\u00e1ndez-Breijo","sequence":"additional","affiliation":[{"name":"Immuno-rheumatology Research Group, La Paz University Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9896-0223","authenticated-orcid":false,"given":"Johanna Elin","family":"Gehin","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"le M\u00e9l\u00e9do","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Tours, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8070-7062","authenticated-orcid":false,"given":"Alejandro","family":"Balsa","sequence":"additional","affiliation":[{"name":"Rheumatology, La Paz University Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1487-277X","authenticated-orcid":false,"given":"Meghna","family":"Jani","sequence":"additional","affiliation":[{"name":"Centre for Epidemiology versus Arthritis, Centre for Musculoskeletal Research, The University of Manchester, Manchester, UK"},{"name":"department of Rheumatology, Salford Royal Hospitals NHS Trust, Salford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4089-7513","authenticated-orcid":false,"given":"Denis","family":"Mulleman","sequence":"additional","affiliation":[{"name":"Rheumatology, University of Tours, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Navarro-Compan","sequence":"additional","affiliation":[{"name":"Rheumatology, La Paz University Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gertjan","family":"Wolbink","sequence":"additional","affiliation":[{"name":"Immunopathology, Sanquin Research, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6103-7056","authenticated-orcid":false,"given":"John D","family":"Isaacs","sequence":"additional","affiliation":[{"name":"Translational and Clinical Research Institute, Newcastle University and Musculoskeletal Unit, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8477-0683","authenticated-orcid":false,"given":"Astrid","family":"van Tubergen","sequence":"additional","affiliation":[{"name":"department of Medicine, Division of Rheumatology, Maastricht University Medical Centre+, Maastricht, The Netherlands"},{"name":"Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,6,3]]},"reference":[{"key":"2025090312292701000_8.2.e002216.1","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s10096-019-03769-8","article-title":"Diagnostic and medical needs for therapeutic drug monitoring of antibiotics","volume":"39","author":"Mabilat","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2025090312292701000_8.2.e002216.2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in Neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"2025090312292701000_8.2.e002216.3","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/apt.14368","article-title":"Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases","volume":"46","author":"Mitrev","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2025090312292701000_8.2.e002216.4","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","article-title":"American gastroenterological association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease","volume":"153","author":"Feuerstein","year":"2017","journal-title":"Gastroenterology"},{"key":"2025090312292701000_8.2.e002216.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212376"},{"key":"2025090312292701000_8.2.e002216.6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/03009742.2016.1183039","article-title":"Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study","volume":"46","author":"Kneepkens","year":"2017","journal-title":"Scand J Rheumatol"},{"key":"2025090312292701000_8.2.e002216.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211781"},{"key":"2025090312292701000_8.2.e002216.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.10302"},{"key":"2025090312292701000_8.2.e002216.9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3109\/03009742.2015.1114666","article-title":"Search for a concentration\u2013effect curve of adalimumab in ankylosing spondylitis patients","volume":"45","author":"Marsman","year":"2016","journal-title":"Scand J Rheumatol"},{"key":"2025090312292701000_8.2.e002216.10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.065615"},{"key":"2025090312292701000_8.2.e002216.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204172"},{"key":"2025090312292701000_8.2.e002216.12","first-page":"110","article-title":"Optimal concentration range of golimumab in patients with axial spondyloarthritis","volume":"36","author":"Mart\u00ednez-Feito","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312292701000_8.2.e002216.13","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/BOR.0000000000000487","article-title":"Therapeutic drug monitoring of biologicals in rheumatoid arthritis: a disconnect between beliefs and facts","volume":"30","author":"den Broeder","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"2025090312292701000_8.2.e002216.14","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/17425255.2017.1353602","article-title":"Clinical utility of therapeutic drug monitoring in biological disease modifying anti-rheumatic drug treatment of rheumatic disorders: a systematic narrative review","volume":"13","author":"Van Herwaarden","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2025090312292701000_8.2.e002216.15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206350"},{"key":"2025090312292701000_8.2.e002216.16","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-016-0384-4","article-title":"Ouzzani m, Hammady H, Fedorowicz Z EA. Rayyan - a web and mobile app for systematic reviews","volume":"5","year":"2016","journal-title":"Syst Rev"},{"key":"2025090312292701000_8.2.e002216.17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4008"},{"key":"2025090312292701000_8.2.e002216.18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"2025090312292701000_8.2.e002216.19","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-4-201302190-00009"},{"key":"2025090312292701000_8.2.e002216.20","unstructured":"Wells GA , Shea B , O\u2019Connell D . The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp [Accessed 29 Jan 2021]."},{"key":"2025090312292701000_8.2.e002216.21","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-3-25"},{"key":"2025090312292701000_8.2.e002216.22","doi-asserted-by":"publisher","DOI":"10.1017\/s0266462305050324"},{"key":"2025090312292701000_8.2.e002216.23","doi-asserted-by":"crossref","first-page":"451","DOI":"10.15403\/jgld.2014.1121.244.adb","article-title":"Comparison of two different techniques to assess adalimumab Trough levels in patients with Crohn's disease","volume":"24","author":"Bodini","year":"2015","journal-title":"J Gastrointestin Liver Dis"},{"key":"2025090312292701000_8.2.e002216.24","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102509","article-title":"Personalized medicine in rheumatoid arthritis: how immunogenicity impacts use of TNF inhibitors","volume":"19","author":"Bodio","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2025090312292701000_8.2.e002216.25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2019.112672","article-title":"Development of a competitive binding homogeneous mobility shift assay for the quantification of adalimumab levels in patient serum","volume":"474","author":"Hock","year":"2019","journal-title":"J Immunol Methods"},{"key":"2025090312292701000_8.2.e002216.26","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1515\/cclm-2019-0202","article-title":"Comparison of a new rapid method for the determination of adalimumab serum levels with two established ELISA kits","volume":"57","author":"Laserna-Mendieta","year":"2019","journal-title":"Clin Chem Lab Med"},{"key":"2025090312292701000_8.2.e002216.27","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/apt.13757","article-title":"Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays","volume":"44","author":"Afonso","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2025090312292701000_8.2.e002216.28","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1590\/s0004-2803.201800000-35","article-title":"Serum infliximab measurement in inflammatory bowel disease patients in remission: a comparative analysis of two different methods in a multicentric Brazilian cohort","volume":"55","author":"Teixeira","year":"2018","journal-title":"Arq Gastroenterol"},{"key":"2025090312292701000_8.2.e002216.29","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/FTD.0000000000000310","article-title":"Comparison of three assays to quantify infliximab, adalimumab, and etanercept serum concentrations","volume":"38","author":"van Bezooijen","year":"2016","journal-title":"Ther Drug Monit"},{"key":"2025090312292701000_8.2.e002216.30","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1515\/cclm-2018-0891","article-title":"Analytical and clinical performance evaluation of two POC tests for therapeutic drug monitoring of infliximab","volume":"57","author":"Van den Bossche","year":"2019","journal-title":"Clin Chem Lab Med"},{"key":"2025090312292701000_8.2.e002216.31","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/apt.14943","article-title":"Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing","volume":"48","author":"Verstockt","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2025090312292701000_8.2.e002216.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2015.07.007"},{"key":"2025090312292701000_8.2.e002216.33","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.cca.2018.05.015","article-title":"Development and validation of a targeted affinity-enrichment and LC-MS\/MS proteomics approach for the therapeutic monitoring of adalimumab","volume":"483","author":"Yang","year":"2018","journal-title":"Clin Chim Acta"},{"key":"2025090312292701000_8.2.e002216.34","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/sji.12572","article-title":"Assays for Infliximab Drug Levels and Antibodies: A\u00a0Matter of Scales and Categories","volume":"86","author":"Bader","year":"2017","journal-title":"Scand J Immunol"},{"key":"2025090312292701000_8.2.e002216.35","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-013-7154-0"},{"key":"2025090312292701000_8.2.e002216.36","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31828d23c3"},{"key":"2025090312292701000_8.2.e002216.37","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2014.106"},{"key":"2025090312292701000_8.2.e002216.38","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv004"},{"key":"2025090312292701000_8.2.e002216.39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.clinbiochem.2019.10.010","article-title":"Comparison of the quantum Blue\u00ae reader point-of-care system versus ELISA technique for therapeutic drug monitoring of infliximab levels","volume":"74","author":"Novakovic","year":"2019","journal-title":"Clin Biochem"},{"key":"2025090312292701000_8.2.e002216.40","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1515\/cclm-2015-0266","article-title":"Comparison study of two commercially available methods for the determination of golimumab and anti-golimumab antibody levels in patients with rheumatic diseases","volume":"53","author":"Mart\u00edn","year":"2015","journal-title":"Clin Chem Lab Med"},{"key":"2025090312292701000_8.2.e002216.41","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1007\/s10620-018-5144-y","article-title":"Comparison of point-of-care and classical immunoassays for the monitoring infliximab and antibodies against infliximab in IBD","volume":"63","author":"Nasser","year":"2018","journal-title":"Dig Dis Sci"},{"key":"2025090312292701000_8.2.e002216.42","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1093\/ibd\/izz202","article-title":"Infliximab and adalimumab concentrations may vary between the enzyme-linked immunosorbent assay and the homogeneous mobility shift assay in patients with inflammatory bowel disease: a prospective cross-sectional observational study","volume":"25","author":"Clarke","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2025090312292701000_8.2.e002216.43","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10067-018-4213-0","article-title":"Clinically important neutralizing anti-drug antibodies detected with an in-house competitive ELISA","volume":"38","author":"Ogri\u010d","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2025090312292701000_8.2.e002216.44","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ab.2018.11.018","article-title":"Detection of anti-adalimumab antibodies in a RA responsive cohort of patients using three different techniques","volume":"566","author":"Real-Fern\u00e1ndez","year":"2019","journal-title":"Anal Biochem"},{"key":"2025090312292701000_8.2.e002216.45","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker124"},{"key":"2025090312292701000_8.2.e002216.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2010.02.021"},{"key":"2025090312292701000_8.2.e002216.47","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/FTD.0b013e3181cc6fef","article-title":"Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritis","volume":"32","author":"Mulleman","year":"2010","journal-title":"Ther Drug Monit"},{"key":"2025090312292701000_8.2.e002216.48","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-009-0195-8"},{"key":"2025090312292701000_8.2.e002216.49","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.030452"},{"key":"2025090312292701000_8.2.e002216.50","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205983"},{"key":"2025090312292701000_8.2.e002216.51","doi-asserted-by":"crossref","unstructured":"Moots RJ , Xavier RM , Mok CC . The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: results from a multinational, real-world clinical practice, non-interventional study. PLoS One 2017;12.","DOI":"10.1371\/journal.pone.0179308"},{"key":"2025090312292701000_8.2.e002216.52","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/17425255.2017.1320390","article-title":"Prediction of successful dose reduction or discontinuation of adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement","volume":"13","author":"Bouman","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2025090312292701000_8.2.e002216.53","doi-asserted-by":"crossref","unstructured":"Chen DY , Chen YM , Tsai WC . Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis. Ann Rheum Dis 2015;74.","DOI":"10.1136\/annrheumdis-2013-203893"},{"key":"2025090312292701000_8.2.e002216.54","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207530"},{"key":"2025090312292701000_8.2.e002216.55","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.clinthera.2018.01.002","article-title":"Methotrexate dose in patients with early rheumatoid arthritis impacts methotrexate polyglutamate pharmacokinetics, adalimumab pharmacokinetics, and efficacy: pharmacokinetic and exposure-response analysis of the concerto trial","volume":"40","author":"Goss","year":"2018","journal-title":"Clin Ther"},{"key":"2025090312292701000_8.2.e002216.56","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1002\/art.39169","article-title":"Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis","volume":"67","author":"Jani","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025090312292701000_8.2.e002216.57","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092833"},{"key":"2025090312292701000_8.2.e002216.58","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.181431"},{"key":"2025090312292701000_8.2.e002216.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2016.04.013"},{"key":"2025090312292701000_8.2.e002216.60","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2147\/BTT.S97234","article-title":"Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab","volume":"10","author":"Benucci","year":"2016","journal-title":"BTT"},{"key":"2025090312292701000_8.2.e002216.61","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket137"},{"key":"2025090312292701000_8.2.e002216.62","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001047","article-title":"Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial","volume":"6","author":"Ducourau","year":"2020","journal-title":"RMD Open"},{"key":"2025090312292701000_8.2.e002216.63","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/cts.12738","article-title":"Early adalimumab and Anti-Adalimumab antibody levels for prediction of primary nonresponse in ankylosing spondylitis patients","volume":"13","author":"Ding","year":"2020","journal-title":"Clin Transl Sci"},{"key":"2025090312292701000_8.2.e002216.64","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00296-019-04288-7","article-title":"Clinical relevance of monitoring serum adalimumab levels in axial spondyloarthritis","volume":"39","author":"Senabre Gallego","year":"2019","journal-title":"Rheumatol Int"},{"key":"2025090312292701000_8.2.e002216.65","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204185"},{"key":"2025090312292701000_8.2.e002216.66","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev298"},{"key":"2025090312292701000_8.2.e002216.67","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s10067-018-04424-x","article-title":"Effective serum level of etanercept biosimilar and effect of antidrug antibodies on drug levels and clinical efficacy in Chinese patients with ankylosing spondylitis","volume":"38","author":"Dong","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2025090312292701000_8.2.e002216.68","first-page":"661","article-title":"The formation of autoantibodies and antibodies to TNF-\u03b1 blocking agents in relation to clinical response in patients with ankylosing spondylitis","volume":"28","author":"Arends","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312292701000_8.2.e002216.69","doi-asserted-by":"publisher","DOI":"10.1002\/art.24275"},{"key":"2025090312292701000_8.2.e002216.70","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.072397"},{"key":"2025090312292701000_8.2.e002216.71","unstructured":"Arends S , Lebbink HR , Spoorenberg A . The formation of autoantibodies and antibodies to TNF-\u03b1 blocking agents in relation to clinical response in patients with ankylosing spondylitis autoantibodies and antibodies to TNF-\u03b1 blocking agents in as \/ S. Arends 2010."},{"key":"2025090312292701000_8.2.e002216.72","doi-asserted-by":"publisher","DOI":"10.1177\/0300060515593235"},{"key":"2025090312292701000_8.2.e002216.73","doi-asserted-by":"crossref","first-page":"R160","DOI":"10.1186\/ar4675","article-title":"Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation","volume":"16","author":"Paramarta","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2025090312292701000_8.2.e002216.74","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200828"},{"key":"2025090312292701000_8.2.e002216.75","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190253"},{"key":"2025090312292701000_8.2.e002216.76","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13075-019-2009-5","article-title":"Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study","volume":"21","author":"Gehin","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2025090312292701000_8.2.e002216.77","first-page":"942","article-title":"Clinical relevance of monitoring serum levels of adalimumab in patients with rheumatoid arthritis in daily practice","volume":"32","author":"Rosas","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312292701000_8.2.e002216.78","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1032-z"},{"key":"2025090312292701000_8.2.e002216.79","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e318224f83d"},{"key":"2025090312292701000_8.2.e002216.80","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-eular.2792","article-title":"Serum golimunab concentratios and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study","volume":"79","author":"Gehin","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025090312292701000_8.2.e002216.81","unstructured":"Stamp L , Keating P , Frampton C , et al . Melanie Millier pH and JO. Relationship between adalimumab concentrations, plasma cytokines, anti-drug antibodies and disease activity in rheumatoid arthritis. Arthritis Rheumatol 2019;71."},{"key":"2025090312292701000_8.2.e002216.82","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.111522"},{"key":"2025090312292701000_8.2.e002216.83","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200184"},{"key":"2025090312292701000_8.2.e002216.84","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/03009742.2018.1433232","article-title":"Concentrations of infliximab and anti-drug antibodies in relation to clinical response in patients with rheumatoid arthritis","volume":"47","author":"Siljehult","year":"2018","journal-title":"Scand J Rheumatol"},{"key":"2025090312292701000_8.2.e002216.85","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-13-184"},{"key":"2025090312292701000_8.2.e002216.86","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.089979"},{"key":"2025090312292701000_8.2.e002216.87","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12509"},{"key":"2025090312292701000_8.2.e002216.88","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204971"},{"key":"2025090312292701000_8.2.e002216.89","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/cts.12502","article-title":"A pilot dose-finding study of etanercept in rheumatoid arthritis","volume":"11","author":"Breedveld","year":"2018","journal-title":"Clin Transl Sci"},{"key":"2025090312292701000_8.2.e002216.90","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/bcp.12142","article-title":"The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis","volume":"76","author":"van den Bemt","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"2025090312292701000_8.2.e002216.91","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208849"},{"key":"2025090312292701000_8.2.e002216.92","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/cts.12760","article-title":"Exposure-Response relationship of Certolizumab pegol and achievement of low disease activity and remission in patients with rheumatoid arthritis","volume":"13","author":"Paul","year":"2020","journal-title":"Clin Transl Sci"},{"key":"2025090312292701000_8.2.e002216.93","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207814"},{"key":"2025090312292701000_8.2.e002216.94","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/jcph.826","article-title":"Pharmacokinetic and pharmacodynamic analysis of subcutaneous tocilizumab in patients with rheumatoid arthritis from 2 randomized, controlled trials: SUMMACTA and BREVACTA","volume":"57","author":"Abdallah","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"2025090312292701000_8.2.e002216.95","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.4989"},{"key":"2025090312292701000_8.2.e002216.96","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205554"},{"key":"2025090312292701000_8.2.e002216.97","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2174\/1874312901711010075","article-title":"Predictive value of serum infliximab levels at induction phase in rheumatoid arthritis patients","volume":"11","author":"Teresa","year":"2017","journal-title":"Open Rheumatol J"},{"key":"2025090312292701000_8.2.e002216.98","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1136\/annrheumdis-2019-eular.4098","article-title":"Trough versus non-trough adalimumab drug level measurements","volume":"79","author":"Hooijberg","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025090312292701000_8.2.e002216.99","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203523"},{"key":"2025090312292701000_8.2.e002216.100","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22110"},{"key":"2025090312292701000_8.2.e002216.101","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3109\/14397595.2014.881954","article-title":"Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a phase II\/III, randomized study","volume":"24","author":"Iwahashi","year":"2014","journal-title":"Mod Rheumatol"},{"key":"2025090312292701000_8.2.e002216.102","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-eular.1320","article-title":"OP0209 Interval Prolongation in patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis: an open-label, randomised controlled trial","volume":"79","author":"L\u2019ami","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025090312292701000_8.2.e002216.103","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s13075-017-1401-2","article-title":"High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the rising study","volume":"19","author":"Takeuchi","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2025090312292701000_8.2.e002216.104","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206149"},{"key":"2025090312292701000_8.2.e002216.105","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/bcp.13500","article-title":"Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. results from a population pharmacokinetic analysis","volume":"84","author":"Bastida","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"2025090312292701000_8.2.e002216.106","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.406"},{"key":"2025090312292701000_8.2.e002216.107","first-page":"145","article-title":"Obesity decreases clinical efficacy and levels of adalimumab in patients with ankylosing spondylitis","volume":"35","author":"Rosas","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312292701000_8.2.e002216.108","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108787"},{"key":"2025090312292701000_8.2.e002216.109","doi-asserted-by":"publisher","DOI":"10.1002\/art.21671"},{"key":"2025090312292701000_8.2.e002216.110","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202591"},{"key":"2025090312292701000_8.2.e002216.111","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162316","article-title":"Anti-drug antibodies, drug levels, interleukin-6 and soluble TNF receptors in rheumatoid arthritis patients during the first 6 months of treatment with adalimumab or infliximab: a descriptive cohort study","volume":"11","author":"Eng","year":"2016","journal-title":"PLoS One"},{"key":"2025090312292701000_8.2.e002216.112","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2018-eular.2979","article-title":"Immunogenicity and loss of response to TNF inhibitors in axial spondyloarthritis: results from an observational cohort study","volume":"77","author":"Ancuta","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025090312292701000_8.2.e002216.113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/604872","article-title":"Influence of immunogenicity on the efficacy of long-term treatment with TNF \u03b1 blockers in rheumatoid arthritis and spondyloarthritis patients","volume":"2015","author":"Arstikyte","year":"2015","journal-title":"Biomed Res Int"},{"key":"2025090312292701000_8.2.e002216.114","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207978"},{"key":"2025090312292701000_8.2.e002216.115","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s40744-019-0157-3","article-title":"Immunogenicity of Sarilumab monotherapy in patients with rheumatoid arthritis who were inadequate responders or intolerant to disease-modifying antirheumatic drugs","volume":"6","author":"Wells","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2025090312292701000_8.2.e002216.116","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.109041"},{"key":"2025090312292701000_8.2.e002216.117","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1007\/s10067-017-3788-1","article-title":"Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis","volume":"36","author":"D'Agostino","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2025090312292701000_8.2.e002216.118","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204769"},{"key":"2025090312292701000_8.2.e002216.119","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206588"},{"key":"2025090312292701000_8.2.e002216.120","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10067-018-4355-0","article-title":"The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors","volume":"38","author":"Mart\u00ednez-Feito","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2025090312292701000_8.2.e002216.121","doi-asserted-by":"publisher","DOI":"10.1186\/ar3350"},{"key":"2025090312292701000_8.2.e002216.122","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-eular.3984","article-title":"Infliximab trough levels and disease activity predict early clinical response in patients with axial spondyloarthritis","volume":"78","author":"Martinez-Feito","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025090312292701000_8.2.e002216.123","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.11.015"},{"key":"2025090312292701000_8.2.e002216.124","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-eular.1082","article-title":"OP0017\u00e2\u20ac\u2026therapeutic drug monitoring compared to standard treatment of patients starting infliximab therapy: results from a multicentre randomised trial of 400 patients","volume":"7912","author":"Syversen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025090312292701000_8.2.e002216.125","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00228-020-02925-w","article-title":"Evaluation of dose-tapering strategies for intravenous tocilizumab in rheumatoid arthritis patients using model-based pharmacokinetic\/pharmacodynamic simulations","volume":"76","author":"Bastida","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"2025090312292701000_8.2.e002216.126","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/rheumatology\/key292","article-title":"Adalimumab drug and antidrug antibody levels do not predict flare risk after stopping adalimumab in RA patients with low disease activity","volume":"58","author":"Lamers-Karnebeek","year":"2019","journal-title":"Rheumatology"},{"key":"2025090312292701000_8.2.e002216.127","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/art.40542","article-title":"Golimumab tapering strategy based on serum drug levels in patients with spondyloarthritis","volume":"70","author":"Redondo","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025090312292701000_8.2.e002216.128","doi-asserted-by":"publisher","DOI":"10.1186\/ar2867"},{"key":"2025090312292701000_8.2.e002216.129","first-page":"136","article-title":"Improved adalimumab dose decision with comprehensive diagnostics data","volume":"36","author":"Z\u00e4nker","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312292701000_8.2.e002216.130","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3389\/fmed.2015.00071","article-title":"Effect of infliximab dose increase in rheumatoid arthritis at different Trough concentrations: a cohort study in clinical practice conditions","volume":"2","author":"Plasencia","year":"2015","journal-title":"Front Med"},{"key":"2025090312292701000_8.2.e002216.131","doi-asserted-by":"publisher","DOI":"10.1002\/art.23969"},{"key":"2025090312292701000_8.2.e002216.132","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-216996"},{"key":"2025090312292701000_8.2.e002216.133","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1080\/03009742.2019.1577915","article-title":"Serum drug concentrations to optimize switching from adalimumab to etanercept in rheumatoid arthritis","volume":"48","author":"L' Ami","year":"2019","journal-title":"Scand J Rheumatol"},{"key":"2025090312292701000_8.2.e002216.134","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jbspin.2015.07.015","article-title":"Effect of serum anti-tumour necrosis factor (TNF) drug Trough concentrations and antidrug antibodies (ADAb) to further anti-TNF short-term effectiveness after switching in rheumatoid arthritis and axial spondyloarthritis","volume":"83","author":"Vincent","year":"2016","journal-title":"Joint Bone Spine"},{"key":"2025090312292701000_8.2.e002216.135","doi-asserted-by":"publisher","DOI":"10.1186\/ar4258"},{"key":"2025090312292701000_8.2.e002216.136","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.135111"},{"key":"2025090312292701000_8.2.e002216.137","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.112847"},{"key":"2025090312292701000_8.2.e002216.138","doi-asserted-by":"publisher","DOI":"10.1185\/03007990902841010"},{"key":"2025090312292701000_8.2.e002216.139","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-008-0866-4"},{"key":"2025090312292701000_8.2.e002216.140","first-page":"1","article-title":"Monitoring drug and antidrug levels: a rational approach in rheumatoid arthritis patients treated with biologic agents who experience inadequate response while being on a stable biologic treatment","volume":"2014","author":"Mazilu","year":"2014","journal-title":"Biomed Res Int"},{"key":"2025090312292701000_8.2.e002216.141","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2018-eular.1946","article-title":"The association of biologic drug-levels with infection risk: results from the British Society for rheumatology biologics register for rheumatoid arthritis","volume":"77","author":"Jani","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025090312292701000_8.2.e002216.142","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/art.39841","article-title":"Brief report: relationship between serum infliximab concentrations and risk of infections in patients treated for spondyloarthritis","volume":"69","author":"Bejan-Angoulvant","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025090312292701000_8.2.e002216.143","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210297"},{"key":"2025090312292701000_8.2.e002216.144","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket017"},{"key":"2025090312292701000_8.2.e002216.145","doi-asserted-by":"publisher","DOI":"10.1002\/art.22214"},{"key":"2025090312292701000_8.2.e002216.146","doi-asserted-by":"publisher","DOI":"10.1002\/art.24001"},{"key":"2025090312292701000_8.2.e002216.147","first-page":"37","article-title":"A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis","volume":"33","author":"Abe","year":"2006","journal-title":"J Rheumatol"},{"key":"2025090312292701000_8.2.e002216.148","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-006-0183-7"},{"key":"2025090312292701000_8.2.e002216.149","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jbspin.2015.04.020","article-title":"The clinical relevance of early anti-adalimumab antibodies detection in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: a prospective multicentre study","volume":"83","author":"Hoxha","year":"2016","journal-title":"Joint Bone Spine"},{"key":"2025090312292701000_8.2.e002216.150","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204101"},{"key":"2025090312292701000_8.2.e002216.151","first-page":"67","article-title":"Cost-effectiveness of routine measuring of serum drug concentrations and anti-drug antibodies in treatment of rheumatoid arthritis patients with TNF-\u03b1 blockers","volume":"10","author":"Laine","year":"2016","journal-title":"Biologics"},{"key":"2025090312292701000_8.2.e002216.152","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew292"},{"key":"2025090312292701000_8.2.e002216.153","unstructured":"National Institute for Health and Care Excellence . Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis, 2019."},{"key":"2025090312292701000_8.2.e002216.154","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2018-eular.5285","article-title":"Barriers against testing anti-TNF drug levels and anti-drug antibodies in routine clinical practice","volume":"77","author":"Gavan","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025090312292701000_8.2.e002216.155","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2018-eular.2315","article-title":"Significant overtreatment with biological drugs is common in routine care for patients where serum drug levels are monitored","volume":"77","author":"Perry","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025090312292701000_8.2.e002216.156","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1001\/jama.2021.4172","article-title":"Effect of therapeutic drug monitoring vs standard therapy during infliximab induction on disease remission in patients with chronic immune-mediated inflammatory diseases: a randomized clinical trial","volume":"325","author":"Syversen","year":"2021","journal-title":"JAMA"},{"key":"2025090312292701000_8.2.e002216.157","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1001\/jama.2021.21316","article-title":"Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune-mediated inflammatory diseases: a randomized clinical trial","volume":"326","author":"Syversen","year":"2021","journal-title":"JAMA"},{"key":"2025090312292701000_8.2.e002216.158","unstructured":"Krieckaert CLM , van Tubergen A , Gehin JE . EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases."}],"updated-by":[{"DOI":"10.1136\/rmdopen-2022-002216corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000}}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2022-002216","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:29:42Z","timestamp":1756927782000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2022-002216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":158,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,6,3]]},"published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1136\/rmdopen-2022-002216"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2022-002216","relation":{"correction":[{"id-type":"doi","id":"10.1136\/rmdopen-2022-002216corr1","asserted-by":"object"}]},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]}}}